Stock listing
OTC:MDRX Veradigm Inc. Stock
Follow Veradigm Inc. into a list and get an email when it puts out news.
Share price · OTC:MDRX
$5.10 USD +0.10 (+2.0%)
Close on Nov 20, 2026
- Day range
- $4.75 – $5.18 USDNov 20, 2026
- Volume
- 67,628 sharesNov 20, 2026
- Market cap
- $555.9M USDAt the close on Nov 20, 2026 · price × 109.0M shares outstanding
- 52-week range
- $3.25 – $5.60 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $409,268 USDMedian day 11,997 shares · 1 day with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026

Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · OTC:MDRX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $5.10 | +0.10 | +2.0% | $5.18 | $5.18 | $4.75 | 67,628 | |
| $5.00 | 0.00 | 0.0% | $4.99 | $5.00 | $4.99 | 1,214 | |
| $5.00 | -0.18 | -3.5% | $4.50 | $5.00 | $4.50 | 651 | |
| $5.18 | +0.18 | +3.6% | $5.18 | $5.18 | $5.18 | 1,313 | |
| $5.00 | +0.025 | +0.5% | $4.75 | $5.00 | $4.75 | 58,628 | |
| $4.975 | +0.225 | +4.7% | $4.975 | $4.975 | $4.975 | 1,195 | |
| $4.75 | 0.00 | 0.0% | $4.75 | $4.75 | $4.75 | 42,682 | |
| $4.75 | 0.00 | 0.0% | $4.95 | $4.95 | $4.75 | 11,997 | |
| $4.75 | -0.05 | -1.0% | $4.95 | $4.95 | $4.75 | 3,183 | |
| $4.80 | -0.10 | -2.0% | $4.925 | $4.95 | $4.75 | 46,421 | |
| $4.90 | -0.025 | -0.5% | $4.78 | $4.90 | $4.78 | 1,483 | |
| $4.925 | +0.175 | +3.7% | $4.925 | $4.925 | $4.925 | 1,272 | |
| $4.75 | -0.20 | -4.0% | $3.45 | $4.95 | $3.45 | 2,480 | |
| $4.95 | -0.05 | -1.0% | $4.755 | $4.95 | $4.75 | 7,108 | |
| $5.00 | +0.25 | +5.3% | $4.76 | $5.00 | $4.75 | 102,500 | |
| $4.75 | -0.25 | -5.0% | $4.75 | $4.75 | $4.75 | 1,500 | |
| $5.00 | +0.25 | +5.3% | $4.98 | $5.00 | $4.95 | 1,600 | |
| $4.75 | 0.00 | 0.0% | $4.98 | $4.98 | $4.75 | 496,600 | |
| $4.75 | -0.20 | -4.0% | $5.00 | $5.00 | $4.75 | 502,300 | |
| $4.95 | +0.05 | +1.0% | $4.75 | $4.95 | $4.75 | 47,800 | |
| $4.90 | +0.15 | +3.2% | $4.75 | $4.90 | $4.75 | 47,100 | |
| $4.75 | 0.00 | 0.0% | $5.00 | $5.00 | $4.75 | 27,100 | |
| $4.75 | -0.25 | -5.0% | $4.755 | $4.755 | $4.00 | 1,023,324 | |
| $5.00 | 0.00 | 0.0% | $5.00 | $5.00 | $4.75 | 20,796 | |
| $5.00 | 0.00 | 0.0% | $5.00 | $5.00 | $4.75 | 39,700 | |
| $5.00 | 0.00 | 0.0% | $5.00 | $5.00 | $5.00 | 800 | |
| $5.00 | 0.00 | 0.0% | $5.00 | $5.00 | $5.00 | 1,800 | |
| $5.00 | -0.065 | -1.3% | $4.75 | $5.00 | $4.75 | 5,300 | |
| $5.065 | -0.025 | -0.5% | $4.75 | $5.065 | $4.75 | 1,502 | |
| $5.09 | +0.09 | +1.8% | $4.60 | $5.09 | $4.60 | 97,200 | |
| $5.00 | 0.00 | 0.0% | $4.75 | $5.00 | $4.75 | 2,200 | |
| $5.00 | 0.00 | 0.0% | $4.75 | $5.00 | $4.75 | 26,500 | |
| $5.00 | 0.00 | 0.0% | $5.00 | $5.00 | $4.75 | 1,606 | |
| $5.00 | 0.00 | 0.0% | $4.50 | $5.00 | $4.00 | 10,142 | |
| $5.00 | 0.00 | 0.0% | $5.14 | $5.14 | $4.75 | 26,100 | |
| $5.00 | -0.14 | -2.7% | $5.00 | $5.00 | $4.75 | 26,000 | |
| $5.14 | +0.14 | +2.8% | $5.10 | $5.14 | $4.75 | 69,400 | |
| $5.00 | -0.05 | -1.0% | $5.10 | $5.10 | $4.00 | 6,298 | |
| $5.05 | +0.05 | +1.0% | $4.85 | $5.05 | $4.75 | 54,568 | |
| $5.00 | +0.05 | +1.0% | $4.60 | $5.03 | $4.60 | 12,300 | |
| $4.95 | +0.14 | +2.9% | $4.90 | $5.03 | $4.65 | 1,158,700 | |
| $4.81 | -0.04 | -0.8% | $4.60 | $4.90 | $4.60 | 4,000 | |
| $4.85 | 0.00 | 0.0% | $4.85 | $4.85 | $4.85 | 0 | |
| $4.85 | +0.15 | +3.2% | $4.88 | $4.88 | $4.81 | 7,400 | |
| $4.70 | -0.10 | -2.1% | $4.60 | $4.88 | $4.60 | 25,500 | |
| $4.80 | -0.08 | -1.6% | $4.61 | $4.80 | $4.61 | 6,900 | |
| $4.88 | +0.02 | +0.4% | $4.90 | $4.90 | $4.60 | 57,600 | |
| $4.86 | +0.009 | +0.2% | $4.60 | $4.90 | $4.60 | 50,605 | |
| $4.851 | +0.251 | +5.5% | $4.895 | $4.90 | $4.77 | 49,631 | |
| $4.60 | +0.05 | +1.1% | $4.56 | $4.65 | $4.55 | 257,200 | |
| $4.55 | -0.10 | -2.2% | $4.65 | $4.70 | $4.55 | 111,400 | |
| $4.65 | -0.20 | -4.1% | $4.65 | $4.80 | $4.65 | 5,000 | |
| $4.85 | +0.04 | +0.8% | $4.00 | $4.875 | $4.00 | 770 | |
| $4.81 | +0.01 | +0.2% | $4.85 | $4.85 | $4.80 | 32,463 | |
| $4.80 | +0.10 | +2.1% | $4.70 | $4.88 | $4.65 | 1,900 | |
| $4.70 | -0.105 | -2.2% | $4.90 | $4.90 | $4.70 | 841 | |
| $4.805 | +0.004 | +0.1% | $4.88 | $4.88 | $4.805 | 6,305 | |
| $4.801 | -0.099 | -2.0% | $4.75 | $4.90 | $4.71 | 64,262 | |
| $4.90 | +0.09 | +1.9% | $4.88 | $4.90 | $4.65 | 323,611 | |
| $4.81 | -0.07 | -1.4% | $4.65 | $4.90 | $4.65 | 2,099 | |
| $4.88 | +0.08 | +1.7% | $4.65 | $4.88 | $4.65 | 2,281 | |
| $4.80 | -0.10 | -2.0% | $4.80 | $4.85 | $4.75 | 3,975 | |
| $4.90 | -0.07 | -1.4% | $4.65 | $4.985 | $4.65 | 352,029 | |
| $4.97 | +0.02 | +0.4% | $4.75 | $5.00 | $4.75 | 63,036 | |
| $4.95 | -0.01 | -0.2% | $4.75 | $4.99 | $4.75 | 4,400 |
- Ticker
- OTC:MDRX
- Asset type
- Stock
- Sector
- Health care
- Industry
- Health care services
- Exchange
- OTC
- Currency
- USD
What changed lately
Latest news release · Oct 21, 2026
Veradigm Product Portfolio Achieves HITRUST i1 Certification
Latest deck · Sep 15, 2026
Investor Presentation (September 2026)
Investor deck · 20 slides
Latest news
Veradigm Product Portfolio Achieves HITRUST i1 Certification
Oct 21, 2026
Closed $4.90 (+3.2%) on Oct 22, 2026
Veradigm Appoints Christian Greyenbuhl as Chief Financial Officer
Apr 6, 2026
Closed $4.27 (-3.0%) on Apr 7, 2026
Veradigm Inc. on 6ix
- Sector
- Health care
- Industry
- Health care services
- News releases
- 2 in the last 12 months · 2 in all · newest Oct 21, 2026 · oldest 2026
- Decks
- 57 decks · latest Sep 15, 2026
Valuation
price Nov 20, 2026
- Enterprise value
- No statements on 6ix yet
- P/E
- No statements on 6ix yet
- EV/sales
- No statements on 6ix yet
- EV/EBITDA
- No statements on 6ix yet
- Price/book
- No statements on 6ix yet
- Gross margin
- No statements on 6ix yet
- Operating margin
- No statements on 6ix yet
- Net margin
- No statements on 6ix yet
- Debt to equity
- No statements on 6ix yet
- Beta vs S&P 500
- -0.30
Health care services: the 10 companies nearest in size, of 419 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Veradigm Inc. · OTC:MDRX | US$555.9M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -0.30 |
| Artemis Medicare Services Ltd. · NSE:ARTEMISMED | US$582.2M | US$582.2M | n/a | n/a | n/a | 5.7× | n/a | 0.0× | n/a |
| Medlive Technology Co., Ltd. · HKEX:2192 | US$581.7M | US$184.1M | 11.6× | 1.9× | 10.9× | 0.8× | 52.1% | 0.0× | n/a |
| NRC Health · NASDAQ:NRC | US$556.5M | US$655.8M | 90.8× | 4.6× | 26.9× | n/a | 4.3% | n/a | 0.74 |
| PT Famon Awal Bros Sedaya Tbk · IDX:PRAY | US$554.2M | US$632.0M | 54.8× | 4.2× | 19.5× | 3.1× | 6.7% | 0.6× | n/a |
| Chularat Hospital PCL · SET:CHG | US$550.6M | US$527.6M | 19.2× | 2.1× | 10.4× | 2.4× | 11.5% | 0.1× | n/a |
| GMR Solutions Inc. · NYSE:GMRS | US$546.7M | US$4.44B | 2.6× | 0.8× | 3.9× | 0.6× | 3.6% | 4.7× | 0.24 |
| Heren Health Co., Ltd. Class A · SZSE:300550 | US$539.5M | US$475.3M | n/a | 8.2× | n/a | 3.3× | −7.2% | 0.0× | n/a |
| SBC Medical Group Holdings Incorporated · NASDAQ:SBC | US$531.7M | US$366.6M | 10.3× | 1.9× | 4.7× | 1.9× | 27.3% | 0.1× | 1.20 |
| Sophia Genetics SA · NASDAQ:SOPH | US$530.3M | US$497.7M | n/a | 5.5× | n/a | 7.8× | −89.2% | 0.9× | 1.74 |
| Vibhavadi Medical Center Public Co. Ltd. · SET:VIBHA | US$520.2M | US$584.8M | 9.6× | 4.8× | 22.7× | 1.6× | 44.3% | 0.3× | n/a |
| Median of the others | US$548.7M | US$554.9M | 11.6× | 4.2× | 10.9× | 2.4× | 6.7% | 0.1× | 0.97 |
Forecasts
1 strong buy · 2 hold · Analysts' consensus from EODHD, read Nov 16, 2026. Not 6ix's view and not investment advice.
- Price target
- 8.00 USD · Analysts' mean
- EPS, year to Dec 2025
- 0.25 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Don Trigg | Chief Executive Officer |
| Christian Greyenbuhl | Chief Financial Officer |
| Lisa Marchlewicz | Senior Vice President of Real-World Evidence |
Board
| Director | Role |
|---|---|
| Bruce Felt | Board Member |
| Carol Zierhoffer | Board Member |
| Dave Stevens | |
| Don Trigg | Chief Executive Officer |
| Jonathan Sacks | Board Member |
| Louis Silverman | Board Member |
| Susan Rodriguez | Board Member |
| Vinit Asar | Board Member |
Events
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Mar 31, 2026 | May 26, 2026 · After close | +3.2% |
| Quarter to Dec 31, 2025 | Feb 27, 2026 | 0.0% |
| Quarter to Sep 30, 2025 | Nov 7, 2025 | −5.0% |
| Quarter to Jun 30, 2025 | Aug 8, 2025 | −2.1% |
| Quarter to Mar 31, 2025 | May 9, 2025 | −6.5% |
| Q4 2024 | Mar 17, 2025 · After close | +0.6% |
| Quarter to Sep 30, 2024 | Nov 1, 2024 | 0.0% |
| Quarter to Jun 30, 2024 | Aug 2, 2024 | −3.9% |
| Quarter to Mar 31, 2024 | May 3, 2024 | −1.3% |
| Quarter to Dec 31, 2023 | Mar 13, 2024 · After close | +3.7% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q3 2023 | Oct 20, 2023 · After close | −0.5% |
| Q2 2023 | Sep 29, 2023 · Before open | −1.8% |
| Q1 2023 | May 10, 2023 · After close | −0.2% |
| Q4 2022 | Mar 1, 2023 · After close | −0.9% |
| Q3 2022 | Nov 3, 2022 · After close | +12.7% |
| Q2 2022 | Aug 4, 2022 · After close | +13.5% |
| Q1 2022 | May 5, 2022 · After close | −6.2% |
| Q4 2021 | Feb 24, 2022 · After close | −4.2% |
| Q3 2021 | Nov 4, 2021 · After close | +6.6% |
| Q2 2021 | Aug 5, 2021 · After close | +1.5% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (September 2026) | Investor deck | 20 slides | Sep 15, 2026 |
| Barclays Healthcare Investor Conference 2024 | Conference | 11 slides | Mar 13, 2024 |
| JP Morgan Healthcare Conference 2024 | Conference | 31 slides | Jan 10, 2024 |
| J.P. Morgan Healthcare Conference 2023 | Conference | 30 slides | Jan 11, 2023 |
| Allscripts Healthcare Solutions — Investor Day (September 2022) | Investor day | 57 slides | Sep 28, 2022 |
| Allscripts Healthcare Solutions — Merger or Acquisition (March 2022) | Merger or acquisition | 14 slides | Mar 3, 2022 |
| Allscripts Healthcare Solutions — J.P. Morgan Virtual Healthcare Conference 2021 | Conference | 16 slides | Jan 12, 2021 |
| Allscripts Healthcare Solutions — Q2 2020 Earnings Presentation | Earnings | 20 slides | Jul 31, 2020 |
| Allscripts Healthcare Solutions — J.P. Morgan Healthcare Conference 2020 | Conference | 23 slides | Jan 14, 2020 |
| Allscripts Healthcare Solutions — J.P. Morgan Healthcare Conference 2019 | Conference | 24 slides | Jan 7, 2019 |
Show 50 decks
This page holds 50 of 57 decks. Open Decks
Financials
Annual, in USD
Income statement
| Line | FY2024 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 588.0M | 588.0M | 577.4M | 1.50B | 1.63B | 1.75B | 1.50B | 1.55B | 1.39B | 1.38B |
| Cost of revenue | 279.6M | 279.6M | 319.3M | 937.0M | 1.06B | 1.03B | 864.9M | 904.9M | 829.0M | 831.9M |
| Gross profit | 308.4M | 308.4M | 258.2M | 565.7M | 574.5M | 724.5M | 632.8M | 645.0M | 557.4M | 546.0M |
| Research and development | 97.9M | 97.9M | 84.8M | 206.1M | 254.5M | 295.8M | 220.2M | 188.1M | 184.8M | 192.8M |
| Selling, general and administrative | 169.2M | 313.8M | 389.9M | 419.8M | 451.0M | 486.3M | 392.9M | 339.2M | 358.7M | |
| Operating income | -27.1M | -19.6M | 75.7M | -57.7M | -99.7M | -95.1M | 12.5M | 67.7M | 31.9M | -39.2M |
| Depreciation and amortization | 115.9M | 115.9M | 72.8M | 87.2M | 250.6M | 192.3M | 157.3M | 136.3M | 161.0M | 174.3M |
| EBITDA | 88.8M | 96.4M | 148.4M | 29.5M | 150.9M | 97.2M | 169.8M | 204.0M | 192.9M | 135.1M |
| Interest expense | 6.35M | 6.35M | 13.2M | 34.3M | 43.2M | 50.9M | 37.5M | 29.5M | 30.0M | 29.3M |
| Income before tax | -63.9M | -63.9M | 157.7M | -149.3M | -281.8M | -62.2M | -190.0M | 31.6M | 570.0K | -68.1M |
| Income tax | -43.8M | 27.9M | -16.7M | -43.3M | -19.0M | -5.51M | 309.0K | 2.63M | -1.66M | |
| Net income | -86.5M | -86.5M | 134.4M | 700.4M | -182.2M | 363.7M | -196.5M | -25.7M | -2.23M | -66.5M |
| Earnings per share, basic | -0.67 | -0.67 | 0.97 | 4.40 | -1.10 | 2.04 | -1.09 | -0.14 | -0.01 | -0.37 |
Balance sheet
| Line | FY2024 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 446.6M | 446.6M | 188.3M | 531.1M | 129.6M | 174.2M | 119.5M | 95.6M | 116.9M | 53.2M |
| Short-term investments | 51.0K | 68.0K | 6.66M | 29.6M | 0 | 18.8M | ||||
| Receivables | 175.7M | 119.1M | 451.9M | 479.5M | 517.7M | 531.7M | 492.6M | 405.2M | 327.8M | 331.6M |
| Inventory | 118.8M | 139.3M | 153.9M | 1 | 1 | 1 | -22.0K | 137.9M | ||
| Current assets | 679.6M | 679.6M | 761.3M | 1.15B | 841.3M | 859.0M | 857.1M | 604.3M | 538.3M | 487.2M |
| Property, plant and equipment | 47.9M | 72.2M | 88.3M | 121.9M | 165.6M | 148.8M | 125.6M | 145.8M | ||
| Goodwill | 532.6M | 532.6M | 974.5M | 974.7M | 974.1M | 1.37B | 1.29B | 1.92B | 1.22B | 1.20B |
| Total assets | 1.50B | 1.50B | 2.43B | 2.92B | 3.21B | 3.18B | 4.23B | 3.83B | 2.68B | 2.46B |
| Accounts payable | 30.8M | 30.8M | 6.20M | 35.9M | 102.8M | 73.2M | 85.7M | 126.1M | 60.0M | 70.8M |
| Current liabilities | 230.3M | 230.3M | 488.4M | 934.8M | 1.21B | 797.7M | 889.6M | 667.1M | 512.9M | 521.4M |
| Long-term debt | 200.4M | 350.1M | 167.6M | 551.0M | 647.5M | 906.7M | 717.9M | 612.4M | 548.7M | |
| Total debt | 219.4M | 372.9M | 283.3M | 1.03B | 669.4M | 937.9M | 1.33B | 625.0M | 566.7M | |
| Total liabilities | 487.2M | 487.2M | 1.02B | 1.25B | 1.92B | 1.60B | 2.64B | 2.17B | 1.26B | 1.18B |
| Shareholders' equity | 1.02B | 1.02B | 1.41B | 1.67B | 1.29B | 1.58B | 1.12B | 1.23B | 1.42B | 1.28B |
| Shares outstanding | 128.9M | 128.9M | 138.7M | 159.3M | 166.3M | 178.5M | 180.8M | 186.2M | 185.1M | 179.8M |
Cash flow
| Line | FY2024 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 115.6M | 115.6M | -75.4M | -106.7M | 46.3M | 67.9M | 279.4M | 269.0M | 211.6M | 103.5M |
| Capital spending | -32.3M | -32.3M | -1.89M | -17.0M | -128.0M | -144.6M | -157.0M | -137.9M | -67.6M | -67.1M |
| Free cash flow | 83.3M | 83.3M | -78.5M | -123.7M | -84.2M | -76.7M | 122.4M | 131.1M | 144.0M | 36.4M |
| Cash from investing | 585.1M | -12.2M | 1.62B | -161.1M | 248.0M | -413.0M | -1.15B | -289.0M | -108.7M | |
| Cash from financing | -444.9M | -444.9M | -258.9M | -1.11B | 67.3M | -293.0M | 198.6M | 865.3M | 142.3M | -4.28M |
| Dividends paid | -580.2M | -374.7M | -1.16B | 0 | 0 | |||||
| Share buybacks | -234.4M | -234.4M | -417.4M | -334.1M | -111.5M | -138.9M | -12.1M | -121.2M | -7.06K | -10.4K |
| Change in cash | 256.2M | 256.2M | -347.0M | 399.9M | -47.3M | 22.3M | 65.9M | -20.3M | 63.7M | -9.78M |
Cap table
Built by 6ix from Veradigm Inc.’s releases
- Common shares
- 108,990,678
- Fully diluted
- 108,990,678
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 108,990,678 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 108,990,678 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Susan Rodriguez Other companies: Monopar Therapeutics Inc. (Chief Commercial and Strategy Officer · Since at least Mar 2, 2026); Avadel Pharmaceuticals PLC (Chief Operating Officer · Since at least May 13, 2025); Heron Therapeutics, Inc. (Director · Sep 20, 2021 – Jan 31, 2025 · Past); Ardelyx, Inc. (Chief Commercial Officer · May 18, 2020 – May 21, 2024 · Past) | Director · Since at least Feb 17, 2023 |
| Louis E. Silverman Other companies: STAAR Surgical Company (Director · Since at least Apr 24, 2025); Insight Molecular Diagnostics Inc. (Director · Since at least Jul 1, 2024) | Director · Since at least Feb 20, 2025 |
| Carol Zierhoffer Other companies: Atlas Air Worldwide Holdings Inc (Director · May 25, 2021 – Mar 17, 2023 · Past) | Board Member · Since at least May 31, 2024 |
| David B Stevens Other companies: Imation Corp (Director · Mar 12, 2012 – May 7, 2014 · Past) | Director · Since at least May 31, 2024 |
| Vinit Asar Other companies: ZimVie Inc (Director · Since at least May 7, 2025) | Director · Since at least Jun 2, 2025 |
| Bruce C Felt Jr | Director · Since at least Mar 19, 2025 |
| Bruce Felt | Board Member · Since at least Nov 5, 2026 |
| Christian Greyenbuhl | Chief Financial Officer · Since at least Apr 6, 2026 |
| Dave Stevens | Director · Since at least Nov 4, 2026 |
| Don Trigg | Chief Executive Officer · Since at least Nov 4, 2026 |
All 25 people
| Person | Seat |
|---|---|
| Eric L Jacobson | SVP Interim General Counsel · Since at least Aug 1, 2025 |
| Greg Garrison | Execuitive Chairman · May 31, 2024 – May 31, 2024 · Past |
| Jay P Bhattacharyya | SVP and General Manager · Since at least Aug 1, 2025 |
| John Motulsky | Director · Since at least May 31, 2025 |
| Jonathan Sacks | Board Member · Since at least Nov 5, 2026 |
| Leah Jones | Chief Financial Officer · Apr 1, 2023 – May 1, 2023 · Past |
| Leland Westerfield | CFO · Jan 1, 2024 – May 31, 2024 · Past |
| Lisa Marchlewicz | Senior Vice President of Real-World Evidence · Since at least Nov 4, 2026 |
| Michael Thoyer | Director · Since at least Mar 24, 2025 |
| Richard J Poulton | CEO, Director · Feb 15, 2023 – Aug 4, 2023 · Past |
| Samir Arora | Director · Since at least Mar 24, 2025 |
| Shih Yin Ho | Director · Feb 17, 2023 – Feb 17, 2023 · Past |
| Tally Baker | CHRO · Since at least Nov 3, 2025 |
| Tejal Vakharia | SVP General Counsel · Since at least Feb 26, 2024 |
| Thomas Langan | CEO · Apr 1, 2025 – May 2, 2025 · Past |
Log in to ask 6ix AI your own questions about Veradigm Inc.